Hypertension is the most common medical disorder during pregnancy, with the majority being due to gestational hypertension (GH) or pre-eclampsia. 1 GH is defi ned as a systolic blood pressure (BP) of ≥140 mm Hg or a diastolic BP of ≥90 mm Hg on at least two occasions ≥4-6 h apart after 20 weeks of gestation in a woman known to be normotensive before pregnancy and before 20 weeks' gestation. 1 2 GH is considered severe if there is a sustained elevation in systolic BP to ≥160 mm Hg (United States and Canada) [1] [2] [3] [4] or ≥170 mm Hg (Royal College of Obstetricians and Gynaecologists, UK, and Australia and New Zealand) 5 6 or in diastolic BP to ≥110 mm Hg. [1] [2] [3] [4] [5] [6] Pre-eclampsia is defi ned as hypertension in association with proteinuria. [1] [2] [3] [4] [5] [6] The reported rate of GH is between 6% and 17% in nulliparous women and between 2% and 4% in multiparous women. 1 The rate of pre-eclampsia is between 2% and 7% in nulliparous women and 1% in multiparous women. 1 In addition, most cases of GH and pre-eclampsia are mild, and the majority (approximately 90%) occur at ≥36 weeks' gestation. 1 2 Management of women with mild GH or pre-eclampsia must always aim at the safety of the mother and the delivery of a newborn who will not require prolonged or intensive neonatal care. Planning should consider fetal gestational age, maternal and fetal status at the time of diagnosis, presence of labour, cervical Bishop score and the wishes of the mother. [1] [2] [3] There is general agreement that women with stable disease at <37 weeks' gestation can benefi t from expectant monitoring. [1] [2] [3] [4] [5] [6] In contrast, the optimum management of those beyond 37 0/7 weeks' gestation is controversial. As expectant monitoring is usually associated with increased risk of progression to severe disease (rate of 10% to 25%) 7 8 and a slightly increased risk for abruption placentae (1%), pulmonary oedema or eclampsia (each less than 1%) and other rare complications, several guidelines recommend all such women undergo induction of labour at 37-38 weeks' gestation; [2] [3] [4] [5] [6] others recommend expectant monitoring until 40 0/7 weeks' gestation, labour rupture of membranes or development of maternal or fetal indication. 1 3 The general practice in the Netherlands is to use expectant monitoring up to 41 0/7 weeks' gestation. All current guidelines are based on expert opinion rather than randomised trials. The HYPITAT trial is the fi rst multicentre trial designed to compare the risks and benefi ts of induction of labour versus expectant monitoring for women at ≥36 0/7 weeks' gestation. The HYPITAT trial was a multicenter open-label randomised controlled trial conducted at 6 academic and 32 non-academic hospitals in the Netherlands. It included 756 women with singleton pregnancy at a gestational age of 36 0/7 to 41 0/7 weeks who had mild GH (n = 496) or mild pre-eclampsia (n = 246); 377 were randomised to induction and 379 to expectant monitoring. The primary outcome was a composite of adverse maternal outcomes: progression to severe disease or HELLP syndrome, eclampsia, pulmonary oedema, abruption placentae, postpartum haemorrhage, thromboembolic disease or death. Secondary outcomes were a composite of adverse neonatal outcomes and rate of caesarean section. The sample size was calculated assuming a 50% reduction in the rate of the primary outcome from 12% in the expectant group to 6% in the induction group. Randomisation was also stratifi ed by centre, parity and Bishop score at enrolment. There were no cases of maternal, fetal or neonatal death and no cases of eclampsia or abruption in either group. Women randomised to the induction group had a signifi cant reduction in the primary outcome (31% vs 44%; relative risk (RR) 0.71, 95% CI 0.59 to 0.86). This reduction was mainly due to differences in the rates of severe hypertension. There were no differences in the overall secondary outcomes. Subgroup analysis revealed signifi cant differences in the primary outcome in the group enrolled with mild pre-eclampsia (33% vs 54%; RR 0.61, 95% CI 0.45 to 0.8) but not in those with mild GH (31% vs 38%; RR 0.81, 95% CI 0.63 to 1.03). Therefore, the sample size was inadequate to answer the study question in those with mild hypertension only.
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Several surprising results emerged from this trial. The rates of adverse maternal outcome were high and similar for those enrolled at 36 and 37 weeks' gestation (45% vs 43%). One would expect the rate of adverse maternal outcomes to increase in those managed with expectant monitoring, as this group will have a prolonged latency period. The fi ndings suggest that women in the induction arm at 36-37 weeks had either more severe disease or a longer interval between induction and delivery. In addition, there were no cases of abruption placentae among 756 patients with mild GH or pre-eclampsia, even among the 379 patients receiving expectant monitoring, despite the fact that at least 30% of the latter group progressed to severe disease. These results refute the idea that expectant monitoring is associated with an increased risk of abruption placentae. Moreover, in the induction group, the rate of caesarean section was lower in nulliparous women and in those with cervical Bishop score <2, refuting the belief that induction of labour in these women increases the rate of caesarean section.
The trial warrants several comments. First, GH was defi ned as diastolic BP ≥95 mm Hg, which is inconsistent with the accepted standard criterion of diastolic BP ≥90 mm Hg recommended by most guidelines. [1] [2] [3] [4] [5] [6] Also, the women with systolic BP ≥160 mm Hg included in the trial are considered to have severe disease by North American defi nitions. [1] [2] [3] [4] Second, patients at 40-41 weeks' gestation were included in the trial even though they are not considered appropriate candidates for expectant monitoring. Indeed, this group had the highest rate of the primary outcomes (48%) among the expectant monitoring group. Third, adherence to the protocol was not adequate, as only 79% of the patients were induced within 24 h as required by the protocol. Fourth, the trial did not have adequate sample size to answer the question of whether induction of labour is associated with reduced maternal morbidity in those with mild GH at 37 0/7 to 39 6/7 weeks' gestation. Nevertheless, the results suggest that induction of labour at ≥37 weeks' gestation is associated with reduced maternal morbidity without a concomitant increase in the rates of caesarean section or adverse neonatal outcome. Consequently, this approach should be incorporated into clinical practice provided that gestational age is well documented and the induction period is not prolonged beyond 48 h.
Finally, all current guidelines based on expert opinion recommend expectant monitoring in mild GH or pre-eclampsia between 34 0/7 and 36 6/7 weeks. Several retrospective and observational studies have reported that 15-30% of these women will progress to severe hypertension or severe pre-eclampsia, [7] [8] [9] [10] and such management is associated with increased rates of abruption placentae, HELLP syndrome and fetal growth restriction. [7] [8] [9] [10] There is an urgent need for randomised trials with adequate sample size to address this issue in those with GH alone and in those with mild pre-eclampsia.
